Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

Importance Imaging biomarkers in Parkinson disease (PD) are increasingly important for
monitoring progression in clinical trials and also have the potential to improve clinical care …

Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

Magnetic resonance imaging (MRI) is a non-invasive technique which can provide
comprehensive, multi-parametric information on brain anatomy, function and metabolism …

Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …

Affective disorders, cognitive decline, and psychosis have long been recognized as common
in Parkinson disease (PD), and other psychiatric disorders include impulse control …

Objective To investigate whether REM sleep behavior disorder (RBD) is associated with
worse motor and cognitive decline in Parkinson disease (PD) Methods Four-hundred twenty …

The limbic system describes a complex of brain structures central for memory, learning, as
well as goal directed and emotional behavior. In addition to pathological studies, recent …

Previous studies have shown that the cholinergic nucleus basalis of Meynert and its white
matter projections are affected in Alzheimer's disease dementia and mild cognitive …

Cognitive decline in Parkinson's disease is related to cholinergic system degeneration,
which can be assessed in vivo using structural MRI markers of basal forebrain volume and …